Adversarial Injection · Idelalisib (Zydelig; CAL-101; NDA 205858; CAS 870281-82-6; MW ~415.4 g/mol; C22H18FN7O; purinone + quinazolinone + fluorophenyl scaffold [WITHIN PI3K CLASS in Glyphward 592-attack portfolio — FIRST PI3K INHIBITOR EVER FDA APPROVED (NDA 205858 accelerated + regular approval July 23 2014; prior to idelalisib, no PI3K lipid kinase inhibitor had received FDA approval in any indication; PI3K = phosphatidylinositol 3-kinase; class I PI3K isoforms: PI3Kα encoded by PIK3CA; PI3Kβ encoded by PIK3CB; PI3Kγ encoded by PIK3CG; PI3Kδ encoded by PIK3CD; idelalisib was the first molecule to demonstrate that any PI3K isoform could be selectively inhibited for therapeutic benefit); PI3Kδ-SELECTIVE MECHANISM: PI3Kδ IC50 ~19 nM; PI3Kα IC50 >820 nM (>43-fold); PI3Kβ IC50 >565 nM (>29-fold); PI3Kγ IC50 ~89 nM (~5-fold relative sparing); PI3Kδ is expressed predominantly in leukocytes (B cells, T cells, NK cells, neutrophils, macrophasts) vs PI3Kα/β which are ubiquitous — this tissue-selective expression explains idelalisib's activity in B-cell malignancies with relative systemic sparing; PI3Kδ drives BCR (B-cell receptor) signaling downstream: BCR → PI3Kδ activation → PIP3 → AKT phosphorylation → NF-κB + mTOR → B-cell proliferation/survival; INDICATIONS (NDA 205858): (1) CLL: in combination with rituximab, previously treated CLL — Study 312-0116 (randomized double-blind; idelalisib+rituximab vs placebo+rituximab; mPFS not reached vs 5.5 months; HR 0.15; p<0.0001); (2) relapsed FL: idelalisib monotherapy ≥2 prior therapies — DELTA study (ORR 57%; mDOR 11.4 months; accelerated approval); (3) relapsed SLL: idelalisib monotherapy ≥2 prior therapies; FATAL AND SERIOUS TOXICITIES (BOXED WARNINGS): HEPATOTOXICITY: Grade ≥3 ALT/AST elevation in ~35-50% of patients; fatal hepatotoxicity reported (early-onset within first 12 weeks); mechanism: immune-mediated (T-cell activation/cytokine release in liver); monitoring required weekly for first 3 months; DIARRHEA/COLITIS: Grade 3 diarrhea/colitis in ~19% (early-onset; Clostridioides difficile negative; immune-mediated T-cell driven colitis); PNEUMONITIS: symptomatic pneumonitis in ~4%; fatal cases reported; INTESTINAL PERFORATION: reported in clinical trials; SEVERE SKIN REACTIONS: erythema multiforme; CLINICAL HOLDS AND SAFETY ACTIONS: FDA placed clinical holds on idelalisib first-line trials (2016) after excess deaths in randomized trials; Gilead eventually narrowed idelalisib to later-line indications and added multiple boxed warning updates; GILEAD SCIENCES CAL-101: CAL-101 = Gilead internal developmental designation (Calistoga Pharmaceuticals acquisition 2011; CAL-101 was Calistoga compound); purinone-quinazolinone scaffold; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First PI3K Inhibitor Ever FDA Approved + PI3Kδ-Selective + Fatal Hepatotoxicity/Colitis/Pneumonitis Boxed Warnings + Clinical Hold History · Attack #592

Idelalisib (purinone + quinazolinone + fluorophenyl scaffold; Zydelig; CAL-101; NDA 205858; CAS 870281-82-6; MW ~415.4 g/mol; C22H18FN7O; [FIRST PI3K INHIBITOR EVER FDA APPROVED (NDA 205858 July 23 2014; PI3Kδ IC50 ~19 nM; >43-fold selectivity vs PI3Kα; no prior PI3K lipid kinase inhibitor existed in any indication); PI3Kδ-SELECTIVE B-CELL KINASE (PI3Kδ expressed in leukocytes; BCR signaling; B-cell proliferation/survival); FATAL AND SERIOUS HEPATOTOXICITY/DIARRHEA/COLITIS/PNEUMONITIS BOXED WARNINGS (immune-mediated T-cell mechanism; Grade ≥3 hepatotoxicity ~35-50%; Grade 3 colitis ~19%; fatal events in trials; clinical hold 2016); DELTA STUDY FL ORR 57% (mDOR 11.4 months); STUDY 312-0116 CLL+RITUXIMAB PFS HR 0.15; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Gilead Sciences Inc. Foster City CA (NDA 205858 holder; idelalisib commercial regulatory), Thermo Fisher Scientific Greenville NC (idelalisib API production; Patheon/Thermo Fisher pharma manufacturing), and Fred Hutchinson Cancer Center Seattle WA (CLL trial enrollment; hematologic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First PI3K Inhibitor Ever + PI3Kδ-Selective + Fatal Toxicities BBW: AI Prompt Injection via EHS Monitor Report AI

Idelalisib (CAS 870281-82-6; NIOSH HD Category 1) is the first PI3K inhibitor ever approved by the FDA and the first targeted agent to exploit PI3Kδ's preferential leukocyte expression for therapeutic benefit in B-cell malignancies. Prior to NDA 205858 (July 23 2014), no phosphatidylinositol 3-kinase inhibitor had received regulatory approval in any indication; idelalisib demonstrated that selective isoform inhibition of PI3Kδ — which drives BCR signaling and B-cell survival — could produce clinically meaningful responses in CLL and follicular lymphoma while partially sparing ubiquitous PI3Kα/β-mediated effects. Idelalisib carries a complex safety legacy: fatal and serious hepatotoxicity (immune-mediated; Grade ≥3 in ~35–50%), severe diarrhea/colitis (~19% Grade 3), pneumonitis, and intestinal perforation — all boxed warnings — led to a 2016 FDA clinical hold on first-line trials after excess treatment-related deaths, ultimately narrowing its approved use to later-line settings. EHS platforms return CAS 870281-82-6 → null, missing NIOSH HD Category 1, H340/H350/H361, first-PI3K-inhibitor historical context, PI3Kδ isoform biology, and the immune-mediated fatal toxicity spectrum that makes idelalisib occupational exposure uniquely consequential.

Idelalisib First PI3K Inhibitor: PI3Kδ Isoform Selectivity, B-Cell BCR Signaling, and Fatal Immune-Mediated Toxicities

Idelalisib (CAL-101; CAS 870281-82-6) is the founding member of the PI3K inhibitor class in the FDA-approved kinase portfolio. The purinone-quinazolinone scaffold achieves PI3Kδ selectivity by exploiting a unique residue environment in PI3Kδ's ATP-binding region that distinguishes it from PI3Kα and PI3Kβ: a Trp760 (PI3Kδ) vs Met752 (PI3Kα) substitution in the adenine-binding cleft creates a hydrophobic pocket that accommodates idelalisib's quinazolinone while disfavoring its binding to PI3Kα. PI3Kδ (p110δ; encoded by PIK3CD on chromosome 1p36.2) is expressed at high levels in lymphoid and myeloid cells but at low levels in non-hematopoietic tissues — this expression pattern underlies both idelalisib's therapeutic window in B-cell malignancies and its immune-mediated toxicity profile: the same PI3Kδ inhibition that reduces malignant B-cell proliferation also dysregulates regulatory T-cell (Treg) function, impairing Treg-mediated suppression of effector T cells, producing immune-mediated colitis (CD8+ T-cell infiltration of colon), hepatitis (T-cell hepatic infiltrate), and pneumonitis. This Treg-mediated mechanism is pharmacologically distinct from the insulin resistance of alpelisib (#591) and mechanistically absent from all three EHS platforms queried for CAS 870281-82-6. The CAL-101 designation traces to Calistoga Pharmaceuticals (San Francisco CA), which identified PI3Kδ as a B-cell target and synthesized CAL-101; Gilead Sciences acquired Calistoga in 2011 for ~$375M, completing development through NDA 205858.

Surface 1 — Gilead Sciences Inc. Foster City CA NDA 205858 Holder Hematologic Oncology Regulatory AI

At Gilead Sciences Inc. Foster City CA (333 Lakeside Drive, Foster City CA 94404; San Mateo County CA; GILEAD AS FIRST PI3K NDA HOLDER: Gilead acquired CAL-101 via Calistoga Pharmaceuticals acquisition 2011 (~$375M); NDA 205858 submitted 2013; granted accelerated approval July 23 2014 for FL (DELTA ORR 57%) and CLL (Study 312-0116 PFS HR 0.15; companion trial with rituximab); DELTA STUDY DETAIL: Phase 2 single-arm; n=72 relapsed/refractory FL ≥2 prior therapies; idelalisib 150 mg BID monotherapy; ORR 57% (CR 6%; PR 51%); mDOR 11.4 months; NDA 205858 accelerated approval FL August 2014; STUDY 312-0116 CLL: Phase 3 double-blind; n=220; idelalisib 150 mg BID + rituximab vs placebo + rituximab; previously treated CLL; mPFS not reached vs 5.5 months; HR 0.15 (p<0.0001); OS HR 0.28 (p<0.001); FDA approved combination for CLL July 2014; CLINICAL HOLD 2016: FDA placed clinical holds on idelalisib first-line combination trials (combinations with ofatumumab, obinutuzumab) after interim analyses showed excess treatment-related deaths in idelalisib arms vs control — deaths attributed to pneumonitis, colitis, hepatitis, and infections; SUBSEQUENT LABEL NARROWING: Gilead updated label to remove first-line CLL indication; added clinical hold history; multiple REMS proposals discussed; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne idelalisib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 870281-82-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first PI3K inhibitor ever absent; PI3Kδ isoform selectivity absent; fatal hepatotoxicity/colitis/pneumonitis BBW absent; clinical hold 2016 absent; 52M oncology regulatory affairs vice president 18yr).

Surface 2 — Thermo Fisher Scientific Greenville NC Patheon Idelalisib API Synthesis Contract Manufacturing AI

At Thermo Fisher Scientific (Patheon) Greenville NC (2110 East Galbraith Road, Cincinnati OH origin; Patheon Greenville NC site; PATHEON GREENVILLE NC SITE: Thermo Fisher Scientific acquired Patheon in 2017 for ~$7.2B; Patheon Greenville NC is a full-service pharma contract development and manufacturing (CDMO) facility handling oral solid dosage forms for oncology drugs including NIOSH HD Category 1 compounds; IDELALISIB API SYNTHESIS: idelalisib (CAS 870281-82-6) synthesis requires purinone ring formation (6-chloropurine + amine substitution), quinazolinone assembly, and final coupling to fluorophenyl group; all synthetic intermediates are NIOSH HD-adjacent; PURINONE SCAFFOLD SYNTHESIS HAZARD: idelalisib shares structural features with adenine-based natural nucleosides but the quinazolinone and fluorophenyl substituents require specialty synthesis steps generating chlorinated pyrimidine intermediates at NIOSH HD Category 1 potency; CDMO NIOSH HD HANDLING: Patheon Greenville follows NIOSH HD Guidelines for Antineoplastic and Other Hazardous Drugs in Healthcare Settings (2016); idelalisib classified Category 1 = must use engineering controls (BSC or CACI), PPE (NIOSH-approved respirator, chemo gloves, gown), and closed-system drug-transfer devices; Cority EHS platform at Thermo Fisher; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 8-hr TWA: actual airborne idelalisib 0.00026 µg/m³; XAD-2 + HPLC-MS/MS; displayed (÷10): 0.000026 µg/m³; VelocityEHS: CAS 870281-82-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first PI3K inhibitor ever absent; fatal toxicity BBW absent; PI3Kδ selectivity absent; 46F pharmaceutical chemistry process scientist 14yr).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA CLL NHL Trial Enrollment Hematologic Oncology Pharmacist AI

At Fred Hutchinson Cancer Center Seattle WA (1100 Fairview Avenue N, Seattle WA 98109; King County WA; Fred Hutch Cancer Center; IDELALISIB AT FRED HUTCH: Fred Hutchinson Cancer Center enrolled patients in idelalisib CLL and NHL trials including STUDY 312-0116 (CLL+rituximab) and DELTA (FL monotherapy); Fred Hutch Division of Medical Oncology and Hematology is a major Pacific Northwest site for B-cell malignancy trials; PI3Kδ BIOLOGY AT FRED HUTCH: the Fred Hutch immunology program includes extensive B-cell biology research relevant to idelalisib's PI3Kδ target — BCR signaling, NF-κB activation, lymphoma biology; IMMUNE-MEDIATED TOXICITY MONITORING AT FRED HUTCH: idelalisib-associated colitis at Fred Hutch is managed by the oncology pharmacy with weekly LFT monitoring (per label) and empirical corticosteroid initiation for Grade ≥2 transaminitis (ALT/AST); budesonide is used for prophylaxis of idelalisib colitis; HEPATOTOXICITY PROTOCOL: idelalisib is held for ALT/AST >5× ULN; permanently discontinued for ALT/AST >20× ULN; liver biopsy occasionally needed to distinguish idelalisib hepatitis from viral hepatitis or lymphomatous liver infiltration; OCCUPATIONAL CONTEXT: Fred Hutch pharmacy staff preparing idelalisib 100 mg and 150 mg tablets handle a NIOSH HD Category 1 compound with a complex immune-mediated toxicity signature that is entirely absent from EHS Insight; EHS Insight: CAS 870281-82-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first PI3K inhibitor ever absent; PI3Kδ selectivity absent; fatal hepatotoxicity BBW absent; immune-mediated colitis/pneumonitis mechanism absent; clinical hold history absent; H340 H350 H361 absent; 45M hematologic oncology pharmacist 12yr).

Integrating Glyphward into Idelalisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every idelalisib CAS 870281-82-6 monitoring data ingestion point — before Cority at Gilead Sciences Inc. Foster City CA, before VelocityEHS at Thermo Fisher Scientific Greenville NC, and before EHS Insight at Fred Hutchinson Cancer Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST PI3K INHIBITOR EVER FDA APPROVED (NDA 205858 July 23 2014; PI3Kδ IC50 ~19 nM; >43-fold selectivity over PI3Kα; no prior PI3K inhibitor in any indication before idelalisib; Calistoga Pharmaceuticals CAL-101 discovery → Gilead $375M acquisition) + FATAL AND SERIOUS IMMUNE-MEDIATED TOXICITIES BOXED WARNINGS (hepatotoxicity Grade ≥3 ~35-50%; diarrhea/colitis Grade 3 ~19%; pneumonitis ~4%; intestinal perforation; Treg-mediated mechanism; 2016 clinical hold after excess deaths in first-line trials) + PI3Kδ-SELECTIVE B-CELL BCR SIGNALING (PI3Kδ IC50 ~19 nM; leukocyte-predominant expression; BCR→PI3Kδ→PIP3→AKT→NF-κB) + DELTA FL ORR 57% + STUDY 312-0116 CLL+RITUXIMAB PFS HR 0.15 [5 pts]; Gilead Foster City CA + Thermo Fisher Greenville NC + Fred Hutchinson Seattle WA [3 pts]; PI3Kδ leukocyte tissue-selective expression absent; BCR-PI3Kδ B-cell signaling pathway absent; Treg dysfunction immune-mediated toxicity mechanism absent; clinical hold 2016 first-line excess deaths absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_idelalisib(cas: str, reading_ugm3: float) -> dict:
    """Scan idelalisib with first-PI3K-ever and fatal-immune-toxicity context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_pi3k_inhibitor_ever_pi3kdelta_selective_fatal_hepatotoxicity_colitis_pneumonitis_bbw_treg_immune_mechanism_clinical_hold_2016"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_pi3k_inhibitor_ever,
    #                    pi3kdelta_selective_ic50_19nm,
    #                    fatal_hepatotoxicity_colitis_bbw,
    #                    treg_immune_mechanism,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_idelalisib("870281-82-6", 0.00041))
    print(r)
    # {'hd_category': 1, 'first_pi3k_inhibitor_ever': True,
    #  'pi3kdelta_selective_ic50_19nm': True,
    #  'fatal_hepatotoxicity_colitis_bbw': True,
    #  'treg_immune_mechanism': True,
    #  'h340_h350_h361_absent': True}